NASDAQ:BRNS Barinthus Biotherapeutics (BRNS) Stock Price, News & Analysis $0.63 +0.01 (+1.68%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$0.62 -0.01 (-0.87%) As of 07/6/2026 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Barinthus Biotherapeutics Stock (NASDAQ:BRNS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BRNS alerts:Sign Up Key Stats Today's Range$0.61▼$0.6550-Day Range$0.60▼$0.7252-Week Range$0.51▼$2.92Volume98,355 shsAverage Volume130,617 shsMarket Capitalization$25.76 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingHold Company Overview Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom. Read More Barinthus Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreBRNS MarketRank™: Barinthus Biotherapeutics scored higher than 35% of companies evaluated by MarketBeat, and ranked 643rd out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingBarinthus Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialBarinthus Biotherapeutics has a consensus price target of $4.00, representing about 534.4% upside from its current price of $0.63.Amount of Analyst CoverageBarinthus Biotherapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Barinthus Biotherapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioBarinthus Biotherapeutics has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Barinthus Biotherapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.06% of the float of Barinthus Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverBarinthus Biotherapeutics has a short interest ratio ("days to cover") of 0.08, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Barinthus Biotherapeutics has recently increased by 575.02%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBarinthus Biotherapeutics does not currently pay a dividend.Dividend GrowthBarinthus Biotherapeutics does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Barinthus Biotherapeutics this week, compared to 2 articles on an average week. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Barinthus Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders8.50% of the stock of Barinthus Biotherapeutics is held by insiders.Percentage Held by Institutions25.20% of the stock of Barinthus Biotherapeutics is held by institutions.Read more about Barinthus Biotherapeutics' insider trading history. Receive BRNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Barinthus Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BRNS Stock News HeadlinesBarinthus Biotherapeutics PLC ADR BRNSJuly 3, 2026 | morningstar.comMBarinthus Biotherapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNSMay 11, 2026 | businesswire.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it. | Banyan Hill Publishing (Ad)Barinthus Biotherapeutics: Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate DevelopmentsApril 30, 2026 | finanznachrichten.deBarinthus in Green on Bringing Out Quarterly NumbersApril 30, 2026 | baystreet.caBarinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate DevelopmentsApril 30, 2026 | globenewswire.comBarinthus Biotherapeutics plc Sponsored ADRApril 10, 2026 | edition.cnn.comBarinthus Bio reports 2025 results and moves forward with planned Clywedog mergerMarch 13, 2026 | msn.comSee More Headlines BRNS Stock Analysis - Frequently Asked Questions How have BRNS shares performed this year? Barinthus Biotherapeutics' stock was trading at $0.7001 at the beginning of 2026. Since then, BRNS stock has decreased by 9.9% and is now trading at $0.6305. How were Barinthus Biotherapeutics' earnings last quarter? Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) announced its earnings results on Thursday, April, 30th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.14. When did Barinthus Biotherapeutics IPO? Barinthus Biotherapeutics (BRNS) raised $110 million in an IPO on Friday, April 30th 2021. The company issued 6,500,000 shares at $16.00-$18.00 per share. How do I buy shares of Barinthus Biotherapeutics? Shares of BRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Barinthus Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Barinthus Biotherapeutics investors own include PayPal (PYPL), Avino Silver & Gold Mines (ASM), Cogent Communications (CCOI), Datadog (DDOG), Intuitive Surgical (ISRG), nCino (NCNO) and Construction Partners (ROAD). Company Calendar Last Earnings4/30/2026Today7/06/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 BRNS's financial health is in the Red zone, according to TradeSmith. BRNS has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BRNS Previous SymbolNASDAQ:BRNS CIK1828185 Webwww.barinthusbio.com Phone44-1865-818-808FaxN/AEmployees107Year FoundedN/APrice Target and Rating Average Price Target for Barinthus Biotherapeutics$4.00 High Price Target$4.00 Low Price Target$4.00 Potential Upside/Downside+534.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$66.43 million Net MarginsN/A Pretax MarginN/A Return on Equity-63.83% Return on Assets-48.77% Debt Debt-to-Equity RatioN/A Current Ratio6.05 Quick Ratio6.05 Sales & Book Value Annual Sales$14.97 million Price / Sales1.72 Cash FlowN/A Price / Cash FlowN/A Book Value$1.82 per share Price / Book0.35Miscellaneous Outstanding Shares40,850,000Free Float37,377,000Market Cap$25.76 million OptionableN/A Beta-0.41 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:BRNS) was last updated on 7/7/2026 by MarketBeat.com Staff. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Barinthus Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
